Pub Date : 2016-12-23DOI: 10.5604/14270994.1228134
Iwona Łapińska, L. Zawadzka-Głos
Introduction. Adenoid and tonsil hypertrophy is widespread in the pediatric population, affecting primarily younger children, aged 3 to 6 years. in 1884, a German pathologist, von Waldeyer-hartz, first described clusters of lymphoid tissue in mucosa of the throat, which he named facial lymphatic ring, known today as Waldeyer’s tonsillar ring. Waldeyer’s ring plays a significant role in the development of immune response by allowing the contact of the immune system with multiple antigens and thus, enabling the development of the specific immunological response. the main points of contact of the body with the external environment are the mucous membranes of the digestive and respiratory systems. Waldeyer’s ring, being at the opening of both systems, has a particular role in the development of immune response, especially during the first years of life. Aim. the aim of the study was to analyze the symptoms presented by children hospitalized in the Clinic of pediatric otolaryngology of the medical University of Warsaw that had been qualified for the surgical removal of the adenoid and/or tonsils. Material and methods. All the patients underwent physical examination, and filled in a survey. the study included 59 hospitalized patients, 2 of which refused to disclose the symptoms associated with adenoid and tonsil hypertrophy that was diagnosed in them. Results. the study involved 59 children aged from 2 to 13 years old. the mean age was 6.2 years. the patients were qualified for adenoidectomy or adenotonsillotomy. in 26 cases, at least one of the parents of the patient smoked in the presence of the child. 28 patients reported nasal obstruction, and 29 denied such symptoms. As many as 41 patients (71.9%) reported snoring during sleep. 45 patients (78.9%) breathed through the mouth. Based on the medical history collected from the parents, 22 patients (37.3%) had upper respiratory tract infection at least once a month, 7 patients – every two weeks, 9 – every two months, 15 – every three months, 5 – every 6 months, and one – once a year. Conclusions. 1. the most common symptom in pediatric patients with adenoid and tonsil hypertrophy is snoring. 2. 1/3 of the children with enlarged tonsils is diagnosed with allergies. 3. Almost 45% of children with hypertrophy of the tonsils are exposed to tobacco smoke. 4. Children with enlarged tonsils have upper respiratory tract infections on average once a month.
{"title":"adenoid and tonsils hypertrophy − symptoms and treatment","authors":"Iwona Łapińska, L. Zawadzka-Głos","doi":"10.5604/14270994.1228134","DOIUrl":"https://doi.org/10.5604/14270994.1228134","url":null,"abstract":"Introduction. Adenoid and tonsil hypertrophy is widespread in the pediatric population, affecting primarily younger children, aged 3 to 6 years. in 1884, a German pathologist, von Waldeyer-hartz, first described clusters of lymphoid tissue in mucosa of the throat, which he named facial lymphatic ring, known today as Waldeyer’s tonsillar ring. Waldeyer’s ring plays a significant role in the development of immune response by allowing the contact of the immune system with multiple antigens and thus, enabling the development of the specific immunological response. the main points of contact of the body with the external environment are the mucous membranes of the digestive and respiratory systems. Waldeyer’s ring, being at the opening of both systems, has a particular role in the development of immune response, especially during the first years of life. Aim. the aim of the study was to analyze the symptoms presented by children hospitalized in the Clinic of pediatric otolaryngology of the medical University of Warsaw that had been qualified for the surgical removal of the adenoid and/or tonsils. Material and methods. All the patients underwent physical examination, and filled in a survey. the study included 59 hospitalized patients, 2 of which refused to disclose the symptoms associated with adenoid and tonsil hypertrophy that was diagnosed in them. Results. the study involved 59 children aged from 2 to 13 years old. the mean age was 6.2 years. the patients were qualified for adenoidectomy or adenotonsillotomy. in 26 cases, at least one of the parents of the patient smoked in the presence of the child. 28 patients reported nasal obstruction, and 29 denied such symptoms. As many as 41 patients (71.9%) reported snoring during sleep. 45 patients (78.9%) breathed through the mouth. Based on the medical history collected from the parents, 22 patients (37.3%) had upper respiratory tract infection at least once a month, 7 patients – every two weeks, 9 – every two months, 15 – every three months, 5 – every 6 months, and one – once a year. Conclusions. 1. the most common symptom in pediatric patients with adenoid and tonsil hypertrophy is snoring. 2. 1/3 of the children with enlarged tonsils is diagnosed with allergies. 3. Almost 45% of children with hypertrophy of the tonsils are exposed to tobacco smoke. 4. Children with enlarged tonsils have upper respiratory tract infections on average once a month.","PeriodicalId":55698,"journal":{"name":"New Medicine","volume":"20 1","pages":"103-106"},"PeriodicalIF":0.0,"publicationDate":"2016-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70679604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-12-23DOI: 10.5604/14270994.1228165
J. Kormos-Tasi, E. gácsi, F. Tóth, A. Czinner, L. Szabó
IntroductIon obesity and hypertension are two most important risk factors for cardiovascular diseases (1, 2). obesity is one of the most common health problems of the developed countries. the prevalence is increasing among adults and children alike. In Hungary, the prevalence in children is 9-10%. In 1998, WHo (World Health organization) classified obesity as a disease. obesity, and other metabolic, endocrine and musculoskeletal diseases that are caused by obesity are seen as one of the biggest public health-related problem nowadays. obesity increases the morbidity and mortality in all the populations.
{"title":"Cardiovascular screening program in children in Budapest","authors":"J. Kormos-Tasi, E. gácsi, F. Tóth, A. Czinner, L. Szabó","doi":"10.5604/14270994.1228165","DOIUrl":"https://doi.org/10.5604/14270994.1228165","url":null,"abstract":"IntroductIon obesity and hypertension are two most important risk factors for cardiovascular diseases (1, 2). obesity is one of the most common health problems of the developed countries. the prevalence is increasing among adults and children alike. In Hungary, the prevalence in children is 9-10%. In 1998, WHo (World Health organization) classified obesity as a disease. obesity, and other metabolic, endocrine and musculoskeletal diseases that are caused by obesity are seen as one of the biggest public health-related problem nowadays. obesity increases the morbidity and mortality in all the populations.","PeriodicalId":55698,"journal":{"name":"New Medicine","volume":"20 1","pages":"136-139"},"PeriodicalIF":0.0,"publicationDate":"2016-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70679797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-12-23DOI: 10.5604/14270994.1228182
Z. Kiss, B. Keserü, Magdolna Sinka, I. Krémer
1Institute for Health Promotion and Clinical Methodology, Department of Clinical Studies, Semmelweis University Faculty of Health Sciences, Budapest, Hungary Head of Department: Professor Klára Gadó, MD, PhD 2Institute for Health Promotion and Clinical Methodology, Department for Epidemiology, Semmelweis University Faculty of Health Sciences, Budapest, Hungary Head of Department: István Barcs, PhD 3Institute of Applied Health Sciences, Department of Clinical Studies in Obstetrics and Gynaecology, Semmelweis University Faculty of Health Sciences, Budapest, Hungary Head of Department: Professor János Rigó, MD, PhD 1, 2, 3Semmelweis University Faculty of Health Sciences, Budapest, Hungary Head of Faculty: Professor Zoltán Zsolt Nagy, MD, PhD
{"title":"diFFiCUlties, heAlth proBlems And proFessionAl sUpport oF diVorCed FAthers liVinG sepArAtely From their Children – eXperienCes in hUnGAry","authors":"Z. Kiss, B. Keserü, Magdolna Sinka, I. Krémer","doi":"10.5604/14270994.1228182","DOIUrl":"https://doi.org/10.5604/14270994.1228182","url":null,"abstract":"1Institute for Health Promotion and Clinical Methodology, Department of Clinical Studies, Semmelweis University Faculty of Health Sciences, Budapest, Hungary Head of Department: Professor Klára Gadó, MD, PhD 2Institute for Health Promotion and Clinical Methodology, Department for Epidemiology, Semmelweis University Faculty of Health Sciences, Budapest, Hungary Head of Department: István Barcs, PhD 3Institute of Applied Health Sciences, Department of Clinical Studies in Obstetrics and Gynaecology, Semmelweis University Faculty of Health Sciences, Budapest, Hungary Head of Department: Professor János Rigó, MD, PhD 1, 2, 3Semmelweis University Faculty of Health Sciences, Budapest, Hungary Head of Faculty: Professor Zoltán Zsolt Nagy, MD, PhD","PeriodicalId":55698,"journal":{"name":"New Medicine","volume":"20 1","pages":"152-160"},"PeriodicalIF":0.0,"publicationDate":"2016-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70679893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-12-23DOI: 10.5604/14270994.1228169
csenge Földvári-nagy, Kincső Földvári-nagy, D. Módos, K. Lenti
1Cambridge Centre for Sixth-form Studies, Cambridge, United Kingdom Principal: Stuart Nicholson 2Illyés Gyula High School, Budaörs, Hungary Head of School: Péter Árendás 3Trefort Ágoston High School, Budapest, Hungary Head of School: Zoltán Csapodi 4Department of Morphology and Physiology, Faculty of Health Sciences, Semmelweis University, Budapest, Hungary Head of Department: Professor Gabriella Dörnyei, PhD
{"title":"CompArAtiVe stUdy oF hyGiene hABits in three diFFerent GroUps in hUnGAry","authors":"csenge Földvári-nagy, Kincső Földvári-nagy, D. Módos, K. Lenti","doi":"10.5604/14270994.1228169","DOIUrl":"https://doi.org/10.5604/14270994.1228169","url":null,"abstract":"1Cambridge Centre for Sixth-form Studies, Cambridge, United Kingdom Principal: Stuart Nicholson 2Illyés Gyula High School, Budaörs, Hungary Head of School: Péter Árendás 3Trefort Ágoston High School, Budapest, Hungary Head of School: Zoltán Csapodi 4Department of Morphology and Physiology, Faculty of Health Sciences, Semmelweis University, Budapest, Hungary Head of Department: Professor Gabriella Dörnyei, PhD","PeriodicalId":55698,"journal":{"name":"New Medicine","volume":"14 1","pages":"140-146"},"PeriodicalIF":0.0,"publicationDate":"2016-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70679835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-09-29DOI: 10.5604/14270994.1222609
Csaba Szekrényesi, Gábor L Sándor, A. Gyenes, Huba J. M. Kiss, T. Filkorn, Z. Nagy
Intoduction. refractive surgery is still one of the most frequently performed procedures in ophthalmology. millions of patients every year are operated with surface lasers as well as with deep or lamellar lasers. The operational technique and tools are constantly improving. Aim. To examine the changes in the temperature of the corneal surface during refractive surgery procedures performed using different types of excimer lasers. Material and methods. 150 eyes of 111 patients were included in the study. The corneal surface temperature was measured with a calibrated eBro Tlc730 infrared thermometer (wTw gmBh, germany) before photorefractive keratectomy (prK), after epithelial removal and immediately after finishing the procedure. The average myopic correction was -3.9 ± 1.9 dpt (ranging from -2.5 dpt to -6.5 dpt). The average age of the patients was 25 ± 3.3 years. Results. using anova variance analysis, a statistically significant difference in the change of the temperature was found between different laser platforms. with the post hoc Bonferroni correction, a significant difference between the mel 80 (carl Zeiss meditec, Jena, germany) and the two other analyzed excimer lasers, mel 70 (carl Zeiss meditec, Jena, germany) and wavelight allegretto 400 (alcon wavelight, erlangen, germany), was found. There was no statistically significant difference between the wavelight allegretto and mel 70 excimer lasers. Conclusions. The moderate cooling effect of the different excimer laser platforms might be related to different airflow systems used in the models. it seems that the rise in the surface temperature is not a causative factor of postoperative subepithelial corneal haze when the procedure is performed with lasers using frequencies lower or equal to 400 hz.
{"title":"the Change of Corneal SurfaCe temperature during SurfaCe refraCtiVe SurgiCal proCedureS performed uSing exCimer laSerS with different repetitiVe frequenCieS","authors":"Csaba Szekrényesi, Gábor L Sándor, A. Gyenes, Huba J. M. Kiss, T. Filkorn, Z. Nagy","doi":"10.5604/14270994.1222609","DOIUrl":"https://doi.org/10.5604/14270994.1222609","url":null,"abstract":"Intoduction. refractive surgery is still one of the most frequently performed procedures in ophthalmology. millions of patients every year are operated with surface lasers as well as with deep or lamellar lasers. The operational technique and tools are constantly improving. Aim. To examine the changes in the temperature of the corneal surface during refractive surgery procedures performed using different types of excimer lasers. Material and methods. 150 eyes of 111 patients were included in the study. The corneal surface temperature was measured with a calibrated eBro Tlc730 infrared thermometer (wTw gmBh, germany) before photorefractive keratectomy (prK), after epithelial removal and immediately after finishing the procedure. The average myopic correction was -3.9 ± 1.9 dpt (ranging from -2.5 dpt to -6.5 dpt). The average age of the patients was 25 ± 3.3 years. Results. using anova variance analysis, a statistically significant difference in the change of the temperature was found between different laser platforms. with the post hoc Bonferroni correction, a significant difference between the mel 80 (carl Zeiss meditec, Jena, germany) and the two other analyzed excimer lasers, mel 70 (carl Zeiss meditec, Jena, germany) and wavelight allegretto 400 (alcon wavelight, erlangen, germany), was found. There was no statistically significant difference between the wavelight allegretto and mel 70 excimer lasers. Conclusions. The moderate cooling effect of the different excimer laser platforms might be related to different airflow systems used in the models. it seems that the rise in the surface temperature is not a causative factor of postoperative subepithelial corneal haze when the procedure is performed with lasers using frequencies lower or equal to 400 hz.","PeriodicalId":55698,"journal":{"name":"New Medicine","volume":"449 1","pages":"79-83"},"PeriodicalIF":0.0,"publicationDate":"2016-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70679667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-09-29DOI: 10.5604/14270994.1222610
Z. Szakács, T. seres, Éva Kellős, M. Simon, A. Horváth, V. Fay, Jelena Karaszova, A. Kontra, olívia lalátka, M. Csóka, G. Domján
{"title":"preValenCe of rem BehaVioral diSorder and rem Sleep without atonia in patientS Suffering from parKinSon’S diSeaSe","authors":"Z. Szakács, T. seres, Éva Kellős, M. Simon, A. Horváth, V. Fay, Jelena Karaszova, A. Kontra, olívia lalátka, M. Csóka, G. Domján","doi":"10.5604/14270994.1222610","DOIUrl":"https://doi.org/10.5604/14270994.1222610","url":null,"abstract":"","PeriodicalId":55698,"journal":{"name":"New Medicine","volume":"20 1","pages":"84-89"},"PeriodicalIF":0.0,"publicationDate":"2016-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70679533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-09-29DOI: 10.5604/14270994.1222604
Daniel Piątek, Emilia Migryt, Kamila Tuzim, Joanna Szydełko, A. Boguszewska-Czubara
From 1997, when Klotho protein was first discovered and named “the anti-aging hormone”, scientists have been thoroughly investigating its biological properties. this protein plays an important role in numerous metabolic pathways that contribute to slower ageing processes. the prevalence of neurodegenerative diseases, impairment of cognitive functions and chronic stress increases with age. additional factors, such as nicotine, rosiglitazone, statins, blood-pressure lowering drugs, calcitriol, magnesium, chronic psychosocial stress and aerobic exercises have an influence on Klotho protein plasma concentration. the research on proteins that increase Klotho plasma levels is important because of broad range of biological processes in which Klotho is engaged. Further studies on this substance could result in new possibilities of treatment for several common diseases.
{"title":"Klotho protein proteCtS againSt aging and niCotine-induCed ChroniC Cellular StreSS","authors":"Daniel Piątek, Emilia Migryt, Kamila Tuzim, Joanna Szydełko, A. Boguszewska-Czubara","doi":"10.5604/14270994.1222604","DOIUrl":"https://doi.org/10.5604/14270994.1222604","url":null,"abstract":"From 1997, when Klotho protein was first discovered and named “the anti-aging hormone”, scientists have been thoroughly investigating its biological properties. this protein plays an important role in numerous metabolic pathways that contribute to slower ageing processes. the prevalence of neurodegenerative diseases, impairment of cognitive functions and chronic stress increases with age. additional factors, such as nicotine, rosiglitazone, statins, blood-pressure lowering drugs, calcitriol, magnesium, chronic psychosocial stress and aerobic exercises have an influence on Klotho protein plasma concentration. the research on proteins that increase Klotho plasma levels is important because of broad range of biological processes in which Klotho is engaged. Further studies on this substance could result in new possibilities of treatment for several common diseases.","PeriodicalId":55698,"journal":{"name":"New Medicine","volume":"20 1","pages":"72-75"},"PeriodicalIF":0.0,"publicationDate":"2016-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70679493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-09-29DOI: 10.5604/14270994.1222613
Magdolna Sinka, I. Barcs, G. Domján, Zsuzsanna Kiss Soósnè
{"title":"ViewS of StudentS of puBliC health inSpeCtor training on further StudieS and employment opportunitieS","authors":"Magdolna Sinka, I. Barcs, G. Domján, Zsuzsanna Kiss Soósnè","doi":"10.5604/14270994.1222613","DOIUrl":"https://doi.org/10.5604/14270994.1222613","url":null,"abstract":"","PeriodicalId":55698,"journal":{"name":"New Medicine","volume":"20 1","pages":"90-97"},"PeriodicalIF":0.0,"publicationDate":"2016-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70679589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-09-29DOI: 10.5604/14270994.1222599
Agnieszka Staniewska
Introduction. diosmin is used to treat and alleviate the symptoms of venous insufficiency and haemorrhoids. diosmin-containing medicinal products have been available in poland since the 1990s with the status of drugs available on prescription in the form of flavonoid fraction containing diosmin, as a form subjected to micronisation or nonmicronised. for several years now, diosmin has been present on the pharmaceutical market in the form of over-the-counter medicines (otC), and dietary supplements containing diosmin are available not only in pharmacies, but also in other outlets. great availability of diosmin raises questions about the safety of a treatment without medical or pharmacist’s supervision. the safety of diosmin use in a daily dose of 2000 mg was confirmed in a double-blind, controlled placebo, randomised, three-arm and parallel, phase iii to evaluate the efficacy and safety of diosmin administered for 4 months in the treatment of cellulite. Aim. the aim of the study was to observe the efficacy and safety of micronised diosmin therapy used in a daily dose of 1000 and 2000 mg for a period of four months. Material and methods. the trial involved 327 patients aged 18 to 55 (mean 37.28, standard deviation of 8.587) meeting the inclusion criteria and not meeting the exclusion criteria. the safety analysis includes and shows in a table the measured parameters immediately prior to the first dose, after 2 and 4 months of therapy. Results. no statistically significant deviations from the standard condition in the following parameters present: complete blood count with differential, fibrinogen concentrations, alanine and aspartate transaminase concentration, urea and creatinine concentration, urinalysis. the therapy did not affect the value of systolic and diastolic blood pressure. no significant adverse actions in the studied groups. Conclusions. the results of a clinical trial cited in this work support the use of micronised diosmin in doses up to 2000 mg per day.
{"title":"Safety of treatment and dietary Supplementation with dioSmin in daily doSeS up to 2000 mg a day","authors":"Agnieszka Staniewska","doi":"10.5604/14270994.1222599","DOIUrl":"https://doi.org/10.5604/14270994.1222599","url":null,"abstract":"Introduction. diosmin is used to treat and alleviate the symptoms of venous insufficiency and haemorrhoids. diosmin-containing medicinal products have been available in poland since the 1990s with the status of drugs available on prescription in the form of flavonoid fraction containing diosmin, as a form subjected to micronisation or nonmicronised. for several years now, diosmin has been present on the pharmaceutical market in the form of over-the-counter medicines (otC), and dietary supplements containing diosmin are available not only in pharmacies, but also in other outlets. great availability of diosmin raises questions about the safety of a treatment without medical or pharmacist’s supervision. the safety of diosmin use in a daily dose of 2000 mg was confirmed in a double-blind, controlled placebo, randomised, three-arm and parallel, phase iii to evaluate the efficacy and safety of diosmin administered for 4 months in the treatment of cellulite. Aim. the aim of the study was to observe the efficacy and safety of micronised diosmin therapy used in a daily dose of 1000 and 2000 mg for a period of four months. Material and methods. the trial involved 327 patients aged 18 to 55 (mean 37.28, standard deviation of 8.587) meeting the inclusion criteria and not meeting the exclusion criteria. the safety analysis includes and shows in a table the measured parameters immediately prior to the first dose, after 2 and 4 months of therapy. Results. no statistically significant deviations from the standard condition in the following parameters present: complete blood count with differential, fibrinogen concentrations, alanine and aspartate transaminase concentration, urea and creatinine concentration, urinalysis. the therapy did not affect the value of systolic and diastolic blood pressure. no significant adverse actions in the studied groups. Conclusions. the results of a clinical trial cited in this work support the use of micronised diosmin in doses up to 2000 mg per day.","PeriodicalId":55698,"journal":{"name":"New Medicine","volume":"20 1","pages":"61-68"},"PeriodicalIF":0.0,"publicationDate":"2016-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70679438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-09-29DOI: 10.5604/14270994.1222601
K. Wroński, J. Kaczor, Z. Masłowski, L. Frąckowiak, Michal Frackowiak
1Department of Surgical Oncology, Hospital Ministry of Internal Affairs with Warmia and Mazury Oncology Centre, Olsztyn, Poland Head of Department: Andrzej Lachowski, MD 2Department of Public Health and Epidemiology, University of Warmia and Mazury in Olsztyn, Poland Head of Department: Professor Anna Abramczyk, MD, PhD 3Faculty of Medicine, Medical University in Gdańsk, Poland Dean of University: Professor Janusz Moryś, MD, PhD
{"title":"pSyChiatriC diSorderS aS a riSK faCtor for warthin’S tumor","authors":"K. Wroński, J. Kaczor, Z. Masłowski, L. Frąckowiak, Michal Frackowiak","doi":"10.5604/14270994.1222601","DOIUrl":"https://doi.org/10.5604/14270994.1222601","url":null,"abstract":"1Department of Surgical Oncology, Hospital Ministry of Internal Affairs with Warmia and Mazury Oncology Centre, Olsztyn, Poland Head of Department: Andrzej Lachowski, MD 2Department of Public Health and Epidemiology, University of Warmia and Mazury in Olsztyn, Poland Head of Department: Professor Anna Abramczyk, MD, PhD 3Faculty of Medicine, Medical University in Gdańsk, Poland Dean of University: Professor Janusz Moryś, MD, PhD","PeriodicalId":55698,"journal":{"name":"New Medicine","volume":"20 1","pages":"69-71"},"PeriodicalIF":0.0,"publicationDate":"2016-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70679477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：